Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
cloZAPine
cloZAPine
Cell Status
NFISA
Exceptions / Designators
Risk Evaluation and Mitigation Strategies (REMS) requires labs (WBC and ANC) prior to dispensing.
Brand names:
CLOZARIL
Form
Strength
TABLET, ORAL
25 mg; 100 mg
Additional Information:
NOVEMBER 2015 P&T MINUTES
Last updated:
Jul. 6, 2021
Black Box Warning:
Agranulocytosis, myocarditis, seizure risk
FDA Drug Safety:
Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
NOVEMBER 2015 P&T MINUTES